Female Alms1-deficient mice develop echocardiographic features of adult but not infantile Alström syndrome cardiomyopathy

McKay EJ
Edinburgh University
June 1, 2024
Dis Model Mech
https://pubmed.ncbi.nlm.nih.gov/38756069/

This article is currently being updated. View its version on PubMed.

https://pubmed.ncbi.nlm.nih.gov/38756069/

Research summary

The study evaluated cardiac function in Alms1-deficient mice to determine whether they recapitulate cardiomyopathy observed in Alström syndrome. Female Alms1-deficient mice developed age-dependent echocardiographic abnormalities consistent with adult-onset cardiomyopathy, including impaired systolic and diastolic function. In contrast, infantile cardiomyopathy, a severe manifestation observed in some Alström syndrome patients, was not reproduced. The findings support a role for ALMS1 in long-term cardiac maintenance and remodeling.

Key outcome of the study

Female Alms1-deficient mice developed adult-onset cardiac dysfunction with echocardiographic abnormalities resembling human Alström syndrome. No evidence of infantile cardiomyopathy was observed, suggesting distinct pathogenic mechanisms between pediatric and adult disease manifestations.

Model

Alms1 Knockout mouse — genOway-developed constitutive loss-of-function model of Alström syndrome

TARGET:
Alms1
Synonyms:
Alström syndrome protein 1

Keywords

Alström syndrome, cardiomyopathy, cardiac remodeling, ciliopathy, rare disease modeling, metabolic syndrome

Technical specifications

Conditional Alms1 Knockout model, longitudinal echocardiography, systolic and diastolic function assessment, sex-specific phenotype analysis, cardiac morphology evaluation, translational cardiomyopathy modeling

Related products

Catalogue product

No items found.

Customized product

No items found.

Catalogue product

Alms1

Used as model for ciliopathy and metabolic syndrome
Scientific excellence

From model design to experimental results
Featured in 600+ scientific articles

Collaborative approach

Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions

Robust validation data on catalog models

Generated with biopharma partners and in-house

Innovative technologies

and guaranteed freedom to operate

Easy access to models

Models with certified health status from professional breeders in US and Europe